阿尔茨海默病相关生物标志物的研究现状及进展

摘要
图/表
参考文献
相关文章 (4)

[1]Hampel H, Shen Y, Walsh DM, et al. Biological markers of amyloid beta-related mechanisms in Alzheimer′s disease［J］. Exp Neurol, 2010, 223(2): 334-346.

［2］ Simonsen AH, Hansson SF, Ruetschi U, et al. Amyloid beta l-40 quantification in CSF: comparison between chromatographic and immunochemical methods［J］. Dement Geriatr Cogn Disord, 2007, 23(4): 246-250.

［3］ Tarawneh R, Holtzman DM. Biomarkers in translational research of Alzheimer′s disease［J］. Neuropharmacology, 2010, 59(4/5): 310-322.

［4］ Gloeckner SF, Meyne F, Wagner F, et al. Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia［J］. J Alzheimers Dis, 2008, 14(1): 17-25.

［5］ Kanai M, Matsubara E, Isoe K, et al. Longitudinal study of cerebrospinal fluid levels of tau, A beta l-40, and A beta l-42(43) in Alzheimer′s disease: a study in Japan ［J］. Ann Neurol, 1998, 44(1): 17-26.

［6］ Wiltfang J, Esselmann H, Bibl M, et al. Amyloid beta peptide ratio 42／40 but not A beta 42 correlates with phospho-Tau in patients with-low and high-CSF A beta 40 load［J］. J Neurochem, 2007, 101(4): 1053-1059.

［7］ ErtekinTaner N, Younkin LH, Yager DM, et al. Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families［J］. Neurology, 2008, 70(8): 596-606.

［8］ Lewczuk P, Kornhuber J, Vanmechelen E, et al. Amyloid beta peptides in plasma in early diagnosis of Alzheimer′s disease: A multicenter study with multiplexing［J］. Exp Neurol, 2010, 223(2): 366-370.

［9］ Fukumoto H, Tennis M, Locascio JJ, et al. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels［J］. Arch Neurol, 2003, 60(7): 958-964.

［10］彭丹涛,许贤豪,孟晓梅,等.老年性痴呆血浆中Aβ1-42、Aβ1-40及p-tau (181P)蛋白的临床诊断意义［J］. 中国神经免疫学和神经病学杂志, 2005, 12(4): 208-211.

［11］ Selkoe DJ. Alzheimer′s disease is a synaptic failure［J］. Science, 2002, 298(5594): 789-791.

［12］ Gustaw KA, Garrett MR, Lee HG, et al. Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis［J］. J Neurochem, 2008, 106(3): 1350-1356.

［13］ GustawRothenberg KA, Siedlak SL, Bonda DJ, et al. Dissociated amyloid-beta antibody levels as a serum biomarker for the progression of Alzheimer′s disease: a population-based study［J］. Exp Gerontol, 2010, 45(1): 47-52.

［14］ Marcello A, Wirths O, SchneiderAxmann T, et al. Reduced levels of IgM autoantibodies against N-truncated pyroglutamate Aβ in plasma of patients with Alzheimer′s disease［J］. Neurobiol Aging, 2011, 32(8): 1379-1387.

［15］ Britschgi M, Olin CE, Johns HT, et al. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer′s disease［J］. Proc Natl Acad Sci U S A, 2009, 106(29): 12145-12150.

［16］ Zoia C, Cogliati T, Tagliabue E, et al. Glutamate transporters in platelets: EAAT1 decrease in aging and Alzheimer′s disease［J］. Neurobiol Aging, 2004, 25(2): 149-157.

［17］ MukaetovaLadinska EB, AbdelAll Z, Dodds S, et al. Platelet immunoglobulin and amyloid precursor protein as potential peripheral biomarkers for Alzheimer′s disease: findings from a pilot study ［J］. Age Ageing, 2012, 41(3): 408-412.

［18］ Padovani A, Borroni B, Colciaghi F, et al. Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer′s disease［J］. Arch Neurol, 2002, 59(1): 71-75.

［19］ Borroni B, Colciaghi F, Corsini P, et al. Early stages of probable Alzheimer′s disease are associated with changes in platelet amyloid precursor protein forms［J］. Neurol Sci, 2002, 23(5): 207-210.

［20］ Vandermeeren M, Mercken M, Vanmechelen E, et al. Detection of tau proteins in normal and Alzheimer′s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay［J］. J Neurochem, 1993, 61(5): 1828-1834.

［21］ Kaiser E, Schnknecht P, Hunt A, et al. CSF levels of total tau protein in patients with mild cognitive impairment and Alzheimer′s disease［J］. Z Cerontol Geriatr, 2008, 41(6): 497-501.

［22］ Hansson O, Zetterberg H, Buchhave P, et al. Association between CSF biomarkers and incipient Alzheimer′s disease in patients with mild cognitive impairment: a follow-up study ［J］. Lancet Neurol, 2006, 5(3): 228-234.

［23］ Gloeckner SF, Meyne F, Wagner F, et al. Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia［J］. J Alzheimer′s Dis, 2008, 14(1): 17-25.

［24］ Ward M. Biomarkers for Alzheimer′s disease［J］. Expert Rev Mol Diagn, 2007, 7(5): 635-646.

［25］ Buerger K, Teipel SJ, Zinkowski R, et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects［J］. Neurology, 2002, 59(4): 627-629.

［26］ Ma J, Brewer HB Jr, Potter H. Alzheimer A beta neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by A beta-related peptides［J］. Neurobiol Aging, 1996, 17(5): 773-780.

［27］ Fagan AM, Watson M, Parsadanian M, et al. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer′s disease［J］. Neurobiol Dis, 2002, 9(3): 305-318.

［28］ Rapoport M, Dawson HN, Binder LI, et al. Tau is essential to beta-amyloid-induced neurotoxicity［J］. Proc Natl Acad Sci U S A, 2002, 99(9): 6364-6369.

［29］ Hoe HS, Freeman J, Rebeck GW. Apolipoprotein E decreases tau kinases and phospho-tau levels in primary neurons［J］. Mol Neurodegener, 2006, 1:18.

［30］ Thambisetty M, An Y, Kinsey A, et al. Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment［J］. Neuroimage, 2012, 59(1): 212-217.

［31］ Thambisetty M, Simmons A, Velayudhan L, et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease［J］. Arch Gen Psychiatry, 2010, 67(7): 739-748.

［32］ Swardfager W, Lanctt K, Rothenburg L, et al. A meta-analysis of cytokines in Alzheimer′s disease［J］. Biol Psychiatry, 2010, 68(10):930-941.

［33］ Huang CW, Wang SJ, Wu SJ, et al. Potential blood biomarker for disease severity in the Taiwanese population with Alzheimer′s disease［J］. Am J Alzheimers Dis Other Demen.2012, Epub ahead of print.

［34］ Laske C, Schmohl M, Leyhe T, et al. Immune profiling in blood identifies sTNF-R1 performing comparably well as biomarker panels for classification of Alzheimer′s disease patients［J］. J Alzheimers Dis,2012,Epub ahead of print.

［35］ Monte SM, Ghanbari K, Frey WH, et al. Characterization of the AD7C-NTP cDNA expression in Alzheimer′s disease and measurement of a 41-kD protein in cerebrospinal fluid［J］. J Clin Invest, 1997, 100(12): 3093-3104.

［36］ Ghanbari H, Ghanbari K, Beheshti I, et al. Biochemical assay for AD7C-NTP in urine as an Alzheimer′s disease marker［J］. J Clin Lab Anal, 1998, 12(5): 285-288.

［37］ Munzar M, Levy S, Rush R, et al. Clinical study of a urinary competitive ELISA for neural thread protein in Alzheimer disease［J］. Neurol Clin Neurophysiol, 2002, 2002(1): 2-8.

［38］ Montine TJ, Beal MF, Cudkowicz ME, et al. Increased CSF F2-isoprostanes concentration in probable AD［J］. Neurology, 1999, 52(3): 562-565.

［39］ Praticò D, Clark CM, Liun F, et al. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease［J］. Arch Neurol, 2002, 59(6): 972-976.

［40］ Zetterberg H, Andreasson U, Hansson O, et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease［J］. Arch Neurol, 2008, 65(8): 1102-1107.

［41］ Hebert S, Horr K, Nicola L, et al. Loss of microRNA cluster miR-29a／b-1 in sporadic Alzheimer′s disease corrlates with increased BACE1／betasecretase expression［J］. Proc Natl Acad Sci U S A, 2008, 105(17): 6415-6420.